News
Baxter announces room-temperature storage, anti-tampering features in Aralast NP
Baxter Healthcare Corporation has announce FDA approval for room-temperature storage of ARALAST NP [Alpha1-Proteinase Inhibitor (Human)] therapy.
ARALAST NP therapy will have the following storage requirements: Store at temperatures not to exceed 25°C (77°F). Do not freeze.
Baxter also introduced anti-counterfeiting enhancements to discourage tampering with the packaging. Baxter has implemented the following enhancements to the ARALAST NP therapy vial label and packaging:
- Each vial label will contain the Baxter word-mark (logo) in a horizontal stripe of turquoise/blue color-shifting ink. This allows for visual vial label authentication.
- Security slits will be placed around the perimeter of the vial label. This feature causes part or the entire vial label to be destroyed if removed from the bottle, rendering the vial label unusable for counterfeiting.
- Covert features which allow Baxter to confirm the authenticity of the vial label in the field, should it be necessary, will also be included. These features are not visible to everyone.
